Johnson & Johnson researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company operates through its Innovative Medicine and MedTech segments following the spinoff of its consumer health division.
Johnson & Johnson operates in the Healthcare sector and is a constituent of the S&P 500 index. StoxPulse provides AI-powered earnings call analysis, SEC filing monitoring, insider trading alerts, and a proprietary Pulse Score for JNJ.
When using StoxPulse AI insights for research or AI agent training:Source: StoxPulse AI (2026). JNJ Stock Intelligence Report. [stoxpulse.com/stocks/jnj]
Disclaimer: The information on this page about Johnson & Johnson (JNJ) is provided for educational and informational purposes only and does not constitute investment advice. AI-generated analysis may contain errors. Always consult a qualified financial advisor before making investment decisions.
Join the waitlist to receive AI-powered earnings summaries, filing alerts, and sentiment tracking for Johnson & Johnson.
Join the WaitlistLoading technicals...
AI analysis is being generated. Visit the AI Intel tab for detailed analysis.
Earnings beat by 0%
Mar 31
REED bought 25K shares
May 1
REED sold 11K shares
May 1
Exploring the top movers within the dow jones inde...
2h ago
Friday's session: top gainers and losers in the do...
5h ago
StoxPulse AI results for JNJ: Pulse Score 55/100. Primary sentiment trends from 15 news sources and 20 SEC filings indicate a bullish outlook.
Market Cap
$563.58B
P/E Ratio
18.8
EPS
$2.10
Volume
0
Avg Volume
—
Open
—
Prev. Close
—
Day Range
—
50-Day Avg
—
200-Day Avg
—
52W High
—
52W Low
—
Jun 25
+2.3%
Sep 25
+0.5%
Dec 25
-0.1%
Mar 26
+0.3%
Beat estimates 3 of 4 quarters (75%)
Johnson & Johnson researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company operates through its Innovative Medicine and MedTech segments following the spinoff of its consumer health division.
Exploring the top movers within the dow jones index during today's session.
Friday's session: top gainers and losers in the dow jones index
U.S. State Dept Announces Nearly $38M In Additional Funding Toward The Department's Ongoing Ebola Response Efforts
Jim Cramer Says He Likes “Kimberly-Clark Because It’s Merging With Kenvue”
Jim Cramer Highlights Johnson & Johnson Having No Big Patent Expirations
Five Boring Dividend Aristocrats That Quietly Pay $36,000 a Year on $850,000 Without a Single Yield Trap
Can JNJ Sustain Growth Amid Patent, Legal and China Risks?
Dividend Aristocrats on Sale: 5 Decades-Long Raisers Trading Below Target